Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
August 7, 2020

ViiV Healthcare gets FDA expanded approval for HIV-1 drug Dovato

Specialist HIV company ViiV Healthcare has secured approval from the US Food and Drug Administration (FDA) for its Dovato (dolutegravir/lamivudine) as a complete regimen to treat HIV-1 infection.

ViiV Healthcare has secured FDA expanded approval for HIV-1drug Dovato. (Credit: Business Wire)